Shortcuts Reviewers 2018

open access

Vol 4, No 2 (2006)
Prace oryginalne (nadesłane)
Published online: 2006-07-11
Get Citation

Choice between three phosphodiesterase type 5 inhibitors (PDE-5). A study of preference among patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)

Sławomir Dutkiewicz
Seksuologia Polska 2006;4(2):57-59.

open access

Vol 4, No 2 (2006)
Prace oryginalne (nadesłane)
Published online: 2006-07-11

Abstract


Background. At present, three PDE5 are available for the treatment of erectile dysfunction: sildenafil, vardenafil and tadalafil. All share common mechanism of action but tadalafil is characterized by longer period of effectiveness. In the aim of this study was to assess the preferences concerning particular PDEPI ’s among patients with BPH and ED.
Material and methods. 39 men with clinically moderately advanced BPH successfully treated with doxazosin (n = 21) and tamsulosin (n = 18) for over one year and presenting with ED were enrolled. Their age ranged from 41 to 70 years (mean 57 yrs.: 19 aged ≤ 60 yrs. and 20 > 60 yrs.). All had moderate ED (Sexual Health Inventory for men - IIEF-5 - score 16-18 and Sexual Quotient score 41-60 points). This three-way cross-over open label consisted of three 6 weeks periods, including 4 weeks of drug administration (either sildenafil 50 mg, vardenafil 10 mg and tadalafil 10 mg, in single doses) and 2 weeks washout. At the end of each 6 study weeks periods patients were assessed (clinical examination, IIEF-5 and SQ scoring) and crossed over to another drug arm for futher 6 weeks and after total of 18 weeks completed the study and filled in a treatment preference questionnaire. The tolerability of treatments was also evaluated.
Results. In the group of 39 patients 22 (56%) indicated tadalafil as the preferred modality; 9 (23%) vardenafil and 6 (15%) sildenafil. Additionally, one patient found vardenafil and tadalafil to be equivalent and another one vardenafil and sildenafil to be equally preferred. The patient preferences did not depend on the age or the type of alpha-blocker administered. All medications were well tolerated. Adverse events were infrequent, observed with all the three PDE-5 and included headache, nasal congestion, flushing and diplopia.
Conclusions. 1. Tadalafil was clearly the most frequently preferred drug in BPH patients with moderate ED. 2. All the three evaluated PDE5 were well tolerated and the adverse reactions were mild and infrequent.

Abstract


Background. At present, three PDE5 are available for the treatment of erectile dysfunction: sildenafil, vardenafil and tadalafil. All share common mechanism of action but tadalafil is characterized by longer period of effectiveness. In the aim of this study was to assess the preferences concerning particular PDEPI ’s among patients with BPH and ED.
Material and methods. 39 men with clinically moderately advanced BPH successfully treated with doxazosin (n = 21) and tamsulosin (n = 18) for over one year and presenting with ED were enrolled. Their age ranged from 41 to 70 years (mean 57 yrs.: 19 aged ≤ 60 yrs. and 20 > 60 yrs.). All had moderate ED (Sexual Health Inventory for men - IIEF-5 - score 16-18 and Sexual Quotient score 41-60 points). This three-way cross-over open label consisted of three 6 weeks periods, including 4 weeks of drug administration (either sildenafil 50 mg, vardenafil 10 mg and tadalafil 10 mg, in single doses) and 2 weeks washout. At the end of each 6 study weeks periods patients were assessed (clinical examination, IIEF-5 and SQ scoring) and crossed over to another drug arm for futher 6 weeks and after total of 18 weeks completed the study and filled in a treatment preference questionnaire. The tolerability of treatments was also evaluated.
Results. In the group of 39 patients 22 (56%) indicated tadalafil as the preferred modality; 9 (23%) vardenafil and 6 (15%) sildenafil. Additionally, one patient found vardenafil and tadalafil to be equivalent and another one vardenafil and sildenafil to be equally preferred. The patient preferences did not depend on the age or the type of alpha-blocker administered. All medications were well tolerated. Adverse events were infrequent, observed with all the three PDE-5 and included headache, nasal congestion, flushing and diplopia.
Conclusions. 1. Tadalafil was clearly the most frequently preferred drug in BPH patients with moderate ED. 2. All the three evaluated PDE5 were well tolerated and the adverse reactions were mild and infrequent.
Get Citation

Keywords

erectile dysfunction; benign prostatic hyperplasia; tadalafil; sildenafil; wardenafil

About this article
Title

Choice between three phosphodiesterase type 5 inhibitors (PDE-5). A study of preference among patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)

Journal

Seksuologia Polska (Polish Sexology)

Issue

Vol 4, No 2 (2006)

Pages

57-59

Published online

2006-07-11

Bibliographic record

Seksuologia Polska 2006;4(2):57-59.

Keywords

erectile dysfunction
benign prostatic hyperplasia
tadalafil
sildenafil
wardenafil

Authors

Sławomir Dutkiewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl